Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The fireside chat is scheduled for September 16 at 8:30 a.m. EDT, with a live webcast and a replay available on the Events & Presentations page of Helus Pharma’s investor relations website.
This appearance at a major healthcare investment conference is significant for Helus Pharma as it provides a platform to engage with institutional investors, analysts, and industry peers. The Morgan Stanley Global Healthcare Conference is one of the largest and most influential gatherings in the healthcare sector, attracting top executives from leading pharmaceutical and biotechnology companies. For Helus Pharma, a clinical-stage company focused on mental health, this exposure could enhance its visibility and credibility among potential investors and partners.
Helus Pharma is committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health.
The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, also a proprietary NSA, is in Phase 2 for generalized anxiety disorder. These programs target conditions that affect millions worldwide and often resist existing therapies, underscoring the potential of Helus Pharma’s pipeline to transform care.
The timing of this conference participation is crucial as Helus Pharma advances its late-stage clinical programs. Positive data from these trials could position the company as a leader in the emerging field of psychedelic-inspired mental health treatments. Moreover, the Breakthrough Therapy Designation for HLP003 may expedite its development and review, potentially bringing a new treatment option to patients sooner.
For more information, the full press release can be accessed at https://ibn.fm/r0jfC. Investors and interested parties can also visit the company’s website at www.helus.com and follow Helus Pharma on X, LinkedIn, YouTube, and Instagram for updates.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. The company’s innovative approach to mental health treatment and its participation in high-profile events like the Morgan Stanley conference reflect its commitment to addressing critical unmet needs in mental health care and creating value for shareholders.
